Literature DB >> 8914773

Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group.

G J Gorse1, E Y Yang, R B Belshe, P W Berman.   

Abstract

Salivary binding antibodies induced by candidate human immunodeficiency virus type 1 (HIV-1) vaccines in healthy, HIV-1 uninfected volunteers were assessed in a clinical trial evaluating intramuscularly injected HIV-1MN recombinant gp120 (rgp120) vaccine alone or with HIV-1IIIB rgp120 vaccine. The two rgp120 vaccines induced envelope glycoprotein-specific immunoglobulin G (IgG) and IgA antibodies in whole saliva and serum.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8914773      PMCID： PMC170445          DOI： 10.1128/cdli.3.6.769-773.1996

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


  26 in total

1.  HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network.

Authors:  G J Gorse; J H Rogers; J E Perry; F K Newman; S E Frey; G B Patel; R B Belshe
Journal:  Vaccine       Date:  1995-02       Impact factor: 3.641

2.  A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV.

Authors:  I de Vincenzi
Journal:  N Engl J Med       Date:  1994-08-11       Impact factor: 91.245

3.  High prevalence of serum IgA HIV-1 infection-enhancing antibodies in HIV-infected persons. Masking by IgG.

Authors:  P A Kozlowski; K P Black; L Shen; S Jackson
Journal:  J Immunol       Date:  1995-06-01       Impact factor: 5.422

4.  Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees.

Authors:  N Barrett; G Eder; F Dorner
Journal:  Biotechnol Ther       Date:  1991

5.  Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine.

Authors:  D H Schwartz; G Gorse; M L Clements; R Belshe; A Izu; A M Duliege; P Berman; T Twaddell; D Stablein; R Sposto
Journal:  Lancet       Date:  1993-07-10       Impact factor: 79.321

6.  Serum IgA-mediated neutralization of HIV type 1.

Authors:  P R Burnett; T C VanCott; V R Polonis; R R Redfield; D L Birx
Journal:  J Immunol       Date:  1994-05-01       Impact factor: 5.422

Review 7.  Reassessment of the impact of mucosal immunity in infection with the human immunodeficiency virus (HIV) and design of relevant vaccines.

Authors:  J Mestecky; S Jackson
Journal:  J Clin Immunol       Date:  1994-09       Impact factor: 8.317

8.  Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.

Authors:  R B Belshe; B S Graham; M C Keefer; G J Gorse; P Wright; R Dolin; T Matthews; K Weinhold; D P Bolognesi; R Sposto
Journal:  JAMA       Date:  1994-08-10       Impact factor: 56.272

9.  Contrasting IgA and IgG neutralization capacities and responses to HIV type 1 gp120 V3 loop in HIV-infected individuals.

Authors:  P A Kozlowski; D Chen; J H Eldridge; S Jackson
Journal:  AIDS Res Hum Retroviruses       Date:  1994-07       Impact factor: 2.205

10.  Modulation of human immunodeficiency virus type 1 infection of human monocytes by IgA.

Authors:  E N Janoff; S M Wahl; K Thomas; P D Smith
Journal:  J Infect Dis       Date:  1995-09       Impact factor: 5.226
View more
  1 in total

Review 1.  Building and testing an effective HIV vaccine.

Authors:  J Kahn
Journal:  West J Med       Date:  1999 Nov-Dec
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.